| PUSI # | Igoa Oloa | Fa'amatalaga |
| CPD100230 | JBJ-04-125-02 R-isomer | |
| CPD3232 | NTN21277 | NTN21277, lea e taʻua o Gefitinib-based PROTAC 3 o se VHL-recruiting PROTAC lea e faʻaosofia ai le faʻaleagaina o le EGFR ma le EGFR mutants ma le DC50 o le 11.7 nM ma le 22.3 nM mo le HCC827 cell (Exon 19 del) ma le H3255 cell (L858R). |
| CPDB3615 | Nazartinib; EGF816; NVS-816 | Nazartinib, e lauiloa foi o le EGF816 ma le NVS-816, o se mea e mafai ona tuʻu tautala, e le mafai ona toe faʻafoʻisia, lona tolu-tupulaga, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, faʻatasi ai ma gaioiga antineoplastic. |
| CPDB0934 | EAI-045 | EAI045 o se malosi ma filifilia EGFR inhbitor. O le EAI045 o loʻo faʻamoemoeina le filifilia o le EGFR mutants e faʻasaʻo vailaʻau ae faʻasaoina le faʻaogaina o le vao. EAI045 faʻalavelave L858R / T790M-mutant EGFR faʻatasi ai ma le malosi maualalo-nanomolar i suʻesuʻega biochemical. |
| CPDB0101 | Poziotinib | O faʻasologa o loʻo iai le poziotinib o loʻo suʻesuʻeina i suʻesuʻega faʻapitoa mo togafitiga o le EGFR-mutant lung adenocarcinoma. |
| CPDB0137 | Osimertinib Mesylate | Osimertinib, e lauiloa foi o le mereletinib ma le AZD-9291, o le tolu-tupulaga EGFR inhibitor, na faʻaalia le folafolaga i suʻesuʻega faʻapitoa ma maua ai le faʻamoemoe mo tagata mamaʻi e maua i le kanesa o le tino ua faʻamalosia i le faʻaogaina o le EGFR. |
